Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 296

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 296
---
 $384 billion (not including unpaid caregiving). |

| ● | Medicare and Medicaid are expected to cover $245 billion,                                                                          
 or 64%, of the total health care and long-term care payments for people with Alzheimer’s disease or other dementias. Out-of-pocket 
 spending is expected to be around $97B in 2025.                                                                                    |

| ● | Total payments for health care, long-term care and hospice                                                            
 care for people with Alzheimer’s disease and other dementias are projected to increase to nearly $1 trillion in 2050. |

The total lifetime cost of care for someone
with dementia is estimated at $371,621.

The figure below, adapted from
the Alzheimer’s Association Report presents percentage changes in selected causes of death between 2000 and 2022 (all ages). While
the proportion of deaths from heart disease, stroke, breast and prostate cancer, and HIV decreased, the proportion of deaths from AD in
the US increased by over 140%.

<div align='center'>Percentage Changes in Selected Causes of Death (All Ages) in the US between 2000 and 2022

167</div>

Over the past 20 years,
several investigational drugs for AD failed in clinical development. These drugs were intended to affect different aspects of AD pathology.
A fundamental challenge of AD is that at the point at which physicians can render a definitive diagnosis, the patient has already suffered
massive neuronal loss leading to overt cognitive dysfunction. Thus, clinical trials that are conducted in patients with advanced disease
at the time of their enrollment may be targeting subjects too late in the disease progression for any meaningful impact on disease by
the drug being tested. However, recently a number of high-profile positive study results, have brought hope for treatment options for
AD, including the TRAILBLAZER-ALZ 2 Phase 3 study done by Eli Lilly and Company (NYSE: LLY) in May 2023 ((https://investor.lilly.com/news-releases/news-release-details/lillysdonanemab-significantly-slowed-cognitive-and-functional)
and the Phase 3 randomized study data for lecanemab done by Eiasi and Biogen in November 2022 (https://investors.biogen.com/news-releases/news-release-details/fda-grants-traditionalapproval- leqembir-lecanemab-irmb). On July 6, 2023, the FDA granted full approval for lecanemab, which